JP2019516674A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516674A5 JP2019516674A5 JP2018555237A JP2018555237A JP2019516674A5 JP 2019516674 A5 JP2019516674 A5 JP 2019516674A5 JP 2018555237 A JP2018555237 A JP 2018555237A JP 2018555237 A JP2018555237 A JP 2018555237A JP 2019516674 A5 JP2019516674 A5 JP 2019516674A5
- Authority
- JP
- Japan
- Prior art keywords
- tablet
- weight
- propylthio
- triazolo
- hydroxyethoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 18
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- OEKWJQXRCDYSHL-FNOIDJSQSA-N ticagrelor Chemical compound C1([C@@H]2C[C@H]2NC=2N=C(N=C3N([C@H]4[C@@H]([C@H](O)[C@@H](OCCO)C4)O)N=NC3=2)SCCC)=CC=C(F)C(F)=C1 OEKWJQXRCDYSHL-FNOIDJSQSA-N 0.000 claims description 13
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- VCVOSERVUCJNPR-UHFFFAOYSA-N cyclopentane-1,2-diol Chemical compound OC1CCCC1O VCVOSERVUCJNPR-UHFFFAOYSA-N 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 5
- 230000007214 atherothrombosis Effects 0.000 claims description 5
- 229960000913 crospovidone Drugs 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 5
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 208000010125 myocardial infarction Diseases 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 208000007536 Thrombosis Diseases 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 2
- 208000023516 stroke disease Diseases 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims 2
- -1 3,4 -Difluorophenyl Chemical group 0.000 claims 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 13
- 238000005550 wet granulation Methods 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 238000007373 indentation Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021167539A JP7254871B2 (ja) | 2016-04-21 | 2021-10-12 | 口腔内崩壊錠 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662325584P | 2016-04-21 | 2016-04-21 | |
| US62/325,584 | 2016-04-21 | ||
| PCT/EP2017/059443 WO2017182589A1 (en) | 2016-04-21 | 2017-04-20 | Orally disintegrating tablets |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021167539A Division JP7254871B2 (ja) | 2016-04-21 | 2021-10-12 | 口腔内崩壊錠 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019516674A JP2019516674A (ja) | 2019-06-20 |
| JP2019516674A5 true JP2019516674A5 (enExample) | 2020-05-28 |
| JP6960941B2 JP6960941B2 (ja) | 2021-11-05 |
Family
ID=58640851
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555237A Active JP6960941B2 (ja) | 2016-04-21 | 2017-04-20 | 口腔内崩壊錠 |
| JP2021167539A Active JP7254871B2 (ja) | 2016-04-21 | 2021-10-12 | 口腔内崩壊錠 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021167539A Active JP7254871B2 (ja) | 2016-04-21 | 2021-10-12 | 口腔内崩壊錠 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10729655B2 (enExample) |
| EP (2) | EP4417537A3 (enExample) |
| JP (2) | JP6960941B2 (enExample) |
| KR (2) | KR102392347B1 (enExample) |
| CN (3) | CN107595789B (enExample) |
| AU (2) | AU2017253367B2 (enExample) |
| BR (1) | BR112018071440A2 (enExample) |
| CO (1) | CO2018012431A2 (enExample) |
| DK (1) | DK3445338T3 (enExample) |
| EA (1) | EA201892150A1 (enExample) |
| ES (1) | ES3014055T3 (enExample) |
| FI (1) | FI3445338T3 (enExample) |
| HR (1) | HRP20250204T1 (enExample) |
| HU (1) | HUE070095T2 (enExample) |
| IL (1) | IL262312B (enExample) |
| LT (1) | LT3445338T (enExample) |
| MA (1) | MA44720B1 (enExample) |
| PE (1) | PE20190372A1 (enExample) |
| PH (1) | PH12018502226A1 (enExample) |
| PL (1) | PL3445338T3 (enExample) |
| PT (1) | PT3445338T (enExample) |
| RS (1) | RS66536B1 (enExample) |
| SG (2) | SG10202107682QA (enExample) |
| SI (1) | SI3445338T1 (enExample) |
| SM (1) | SMT202500081T1 (enExample) |
| WO (1) | WO2017182589A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111450067A (zh) * | 2019-01-18 | 2020-07-28 | 北京万全德众医药生物技术有限公司 | 一种替格瑞洛分散片及其制备方法 |
| CN109700773B (zh) * | 2019-03-01 | 2021-03-16 | 石药集团中奇制药技术（石家庄）有限公司 | 一种替格瑞洛制剂组合物及其制备方法 |
| JP7657041B2 (ja) | 2020-08-19 | 2025-04-04 | アストラゼネカ・アクチエボラーグ | 併用療法 |
| CN114712317A (zh) * | 2021-01-04 | 2022-07-08 | 弘和制药有限公司 | 一种替格瑞洛药物组合物及其制备方法和其应用 |
| US20220387328A1 (en) * | 2021-06-04 | 2022-12-08 | Glaxosmithkline Consumer Healthcare Holdings (Us) Llc | Dosage form for nicotine replacement therapy |
| WO2023057879A1 (en) * | 2021-10-04 | 2023-04-13 | Neurim Pharmaceuticals (1991) Ltd. | Methods and products for treating subjects with autism spectrum disorders |
| CN120129530A (zh) | 2022-10-28 | 2025-06-10 | 阿斯利康(瑞典)有限公司 | 以40mg至240mg的剂量用于在治疗缺血事件中使用的重组腺苷三磷酸双磷酸酶蛋白 |
| CN116370423B (zh) * | 2023-02-28 | 2024-11-12 | 天津力生制药股份有限公司 | 一种替格瑞洛口腔崩解片及其制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB516834A (en) * | 1937-12-23 | 1940-01-12 | Charles Alexandre Nicolle | Improvements in or relating to packaging |
| DE2246013A1 (de) | 1972-09-20 | 1974-03-28 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von poroesen tabletten |
| TWI229674B (en) | 1998-12-04 | 2005-03-21 | Astra Pharma Prod | Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses |
| GB0013407D0 (en) | 2000-06-02 | 2000-07-26 | Astrazeneca Ab | Forms of a chemical compound |
| ES2268020T3 (es) * | 2001-05-10 | 2007-03-16 | Astellas Pharma Inc. | Comprimidos de disgregacion rapida de la cavidad oral y proceso para producir los mismos. |
| US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
| CN2717851Y (zh) | 2004-05-14 | 2005-08-17 | 重庆康刻尔制药有限公司 | 一种药品包装板 |
| TWI482772B (zh) | 2006-08-21 | 2015-05-01 | Astrazeneca Ab | 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物 |
| CN102058889A (zh) * | 2010-11-05 | 2011-05-18 | 王定豪 | 包含抗凝血类药物的分散片及其应用 |
| FR2968992B1 (fr) | 2010-12-16 | 2013-02-08 | Sanofi Aventis | Comprime pharmaceutique orodispersible a base de zolpidem |
| US20130160408A1 (en) | 2011-12-22 | 2013-06-27 | Gregor N. Neff | Blister Pack and Method |
| WO2013115171A1 (ja) | 2012-02-03 | 2013-08-08 | 旭化成ケミカルズ株式会社 | 苦味マスク顆粒含有口腔内崩壊錠 |
| CZ2012705A3 (cs) * | 2012-10-16 | 2014-04-23 | Zentiva, K.S. | Pevná orální farmaceutická formulace obsahující ticagrelor |
| CN103964066B (zh) * | 2013-02-06 | 2017-09-19 | 李和伟 | 一种冻干赋型制剂的包装装置 |
| WO2015110952A1 (en) | 2014-01-21 | 2015-07-30 | Wockhardt Limited | Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof |
| CN104650091B (zh) * | 2014-01-24 | 2016-10-05 | 福州乾正药业有限公司 | 替格瑞洛的微粉化及其晶型，以及制备方法和药物应用 |
| EA201691582A1 (ru) * | 2014-02-07 | 2017-01-30 | Оспекс Фармасьютикалз, Инк. | Новые фармацевтические препараты |
-
2017
- 2017-04-20 CN CN201710898954.2A patent/CN107595789B/zh active Active
- 2017-04-20 ES ES17720055T patent/ES3014055T3/es active Active
- 2017-04-20 HR HRP20250204TT patent/HRP20250204T1/hr unknown
- 2017-04-20 PE PE2018002028A patent/PE20190372A1/es unknown
- 2017-04-20 IL IL262312A patent/IL262312B/en unknown
- 2017-04-20 EP EP24187449.4A patent/EP4417537A3/en active Pending
- 2017-04-20 SM SM20250081T patent/SMT202500081T1/it unknown
- 2017-04-20 EA EA201892150A patent/EA201892150A1/ru unknown
- 2017-04-20 EP EP17720055.7A patent/EP3445338B1/en active Active
- 2017-04-20 LT LTEPPCT/EP2017/059443T patent/LT3445338T/lt unknown
- 2017-04-20 US US16/095,090 patent/US10729655B2/en active Active
- 2017-04-20 RS RS20250181A patent/RS66536B1/sr unknown
- 2017-04-20 CN CN201780000516.8A patent/CN107530288B/zh active Active
- 2017-04-20 PL PL17720055.7T patent/PL3445338T3/pl unknown
- 2017-04-20 FI FIEP17720055.7T patent/FI3445338T3/fi active
- 2017-04-20 CN CN201710899077.0A patent/CN107595790B/zh active Active
- 2017-04-20 PT PT177200557T patent/PT3445338T/pt unknown
- 2017-04-20 DK DK17720055.7T patent/DK3445338T3/da active
- 2017-04-20 MA MA44720A patent/MA44720B1/fr unknown
- 2017-04-20 KR KR1020187033221A patent/KR102392347B1/ko active Active
- 2017-04-20 WO PCT/EP2017/059443 patent/WO2017182589A1/en not_active Ceased
- 2017-04-20 KR KR1020227013818A patent/KR102488486B1/ko active Active
- 2017-04-20 SG SG10202107682QA patent/SG10202107682QA/en unknown
- 2017-04-20 SG SG11201808996SA patent/SG11201808996SA/en unknown
- 2017-04-20 BR BR112018071440A patent/BR112018071440A2/pt not_active Application Discontinuation
- 2017-04-20 SI SI201731586T patent/SI3445338T1/sl unknown
- 2017-04-20 JP JP2018555237A patent/JP6960941B2/ja active Active
- 2017-04-20 HU HUE17720055A patent/HUE070095T2/hu unknown
- 2017-04-20 AU AU2017253367A patent/AU2017253367B2/en active Active
-
2018
- 2018-10-18 PH PH12018502226A patent/PH12018502226A1/en unknown
- 2018-11-19 CO CONC2018/0012431A patent/CO2018012431A2/es unknown
-
2020
- 2020-03-18 AU AU2020201930A patent/AU2020201930B2/en active Active
-
2021
- 2021-10-12 JP JP2021167539A patent/JP7254871B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019516674A5 (enExample) | ||
| JP6545839B2 (ja) | 口腔内崩壊錠及びその製造方法 | |
| AU2020201930B2 (en) | Orally disintegrating tablets | |
| US9278063B2 (en) | Press-coated orally-disintegrating tablets | |
| EA023807B1 (ru) | Устойчивые оральные фармацевтические дозированные формы, содержащие опиоидный анальгетик | |
| NZ536046A (en) | High dosage tablet forms of imatinib mesylate | |
| JP2011098964A5 (enExample) | ||
| JP2017500303A (ja) | エゼチミブ及びロスバスタチンを含む経口用複合製剤 | |
| JP2019116514A (ja) | 医薬製剤 | |
| CN105338970B (zh) | 包含他达拉非和坦洛新的药物胶囊复合制剂 | |
| CN101404982A (zh) | 脂族胺聚合物的药物制剂和它们的制造方法 | |
| MX2011013091A (es) | Un antagonista del receptor de trombina y tableta con dosificacion fija de clopidogrel. | |
| CN105377240A (zh) | 固体药物剂型 | |
| JP6276287B2 (ja) | フェキソフェナジン高含有固形単位およびその製造法 | |
| CN105407925A (zh) | 用于泡腾剂型的制造工艺 | |
| KR20160060764A (ko) | 아타자나비르 및 코비시스타트의 ｈｉｖ 치료 제제 | |
| JP6461142B2 (ja) | イソニアジドの顆粒およびリファペンチンの顆粒を含むコーティング錠の形態の抗結核性の安定な医薬組成物ならびにその製造方法 | |
| CN102846573B (zh) | 水飞蓟宾双层缓释片及其制备方法 | |
| CN101203246B (zh) | 药物组合物 | |
| JP2013203690A (ja) | 口腔内崩壊錠及びその製造方法 | |
| TWI651101B (zh) | 包含阿托發司他汀（ａｔｏｒｖａｓｔａｔｉｎ）、厄貝沙坦（ｉｒｂｅｓａｒｔａｎ）及碳酸鎂之雙層複合片劑調配物 | |
| JP2012046454A (ja) | 内服用錠剤およびその製造方法 | |
| RU2677649C2 (ru) | Фармацевтические композиции монтелукаста и левоцетиризина | |
| CN114146089A (zh) | 含依非韦伦、替诺福韦和恩曲他滨的药物组合物 | |
| HK1249733B (zh) | 口腔崩解片 |